Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.biomaterials.2021.120986 http://scihub22266oqcxt.onion/10.1016/j.biomaterials.2021.120986 34175563!8218594!34175563     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Biomaterials 2021 ; 275 (ä): 120986 Nephropedia Template TP {{tp|p=34175563|t=2021. A bilirubin-derived nanomedicine attenuates the pathological cascade of pulmonary fibrosis |pdf=|usr=}}{{34175563}} gab.com Text A bilirubin-derived nanomedicine attenuates the pathological cascade of pulmonary fibrosis JO: Biomaterials http://www.kidney.de/pget.php?&tw=1&pmid=34175563 #FOAvip Pulmonary fibrosis is an irreparable and life-threatening disease with only limited therapeutic options. The recent outbreak of COVID-19 has caused a sharp rise in the incidence of pulmonary fibrosis owing to SARS-CoV-2 infection-mediated acute respiratory distress syndrome (ARDS). The considerable oxidative damage caused by locally infiltrated immune cells plays a crucial role in ARDS, suggesting the potential use of antioxidative therapeutics. Here, we report the therapeutic potential of nanoparticles derived from the endogenous antioxidant and anti-inflammatory bile acid, bilirubin (BRNPs), in treating pulmonary fibrosis in a bleomycin-induced mouse model of the disease. Our results demonstrate that BRNPs can effectively reduce clinical signs in mice, as shown by histological, disease index evaluations, and detection of biomarkers. Our findings suggest that BRNPs, with their potent antioxidant and anti-inflammatory effects, long blood circulation half-life, and preferential accumulation at the inflamed site, are potentially a viable clinical option for preventing Covid-19 infection-associated pulmonary fibrosis. Twit Text FOAVip A bilirubin-derived nanomedicine attenuates the pathological cascade of pulmonary fibrosis ????Biomaterials http://www.kidney.de/pget.php?&tw=1&pmid=34175563 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34175563 #FOAvip English Wikipedia <ref>{{Cite pmid|34175563}}</ref> A bilirubin-derived nanomedicine attenuates the pathological cascade of pulmonary fibrosis #MMPMID34175563 Keum H; Kim D; Kim J; Kim TW; Whang CH; Jung W; Jon S Biomaterials 2021[Aug]; 275 (ä): 120986 PMID34175563show ga Pulmonary fibrosis is an irreparable and life-threatening disease with only limited therapeutic options. The recent outbreak of COVID-19 has caused a sharp rise in the incidence of pulmonary fibrosis owing to SARS-CoV-2 infection-mediated acute respiratory distress syndrome (ARDS). The considerable oxidative damage caused by locally infiltrated immune cells plays a crucial role in ARDS, suggesting the potential use of antioxidative therapeutics. Here, we report the therapeutic potential of nanoparticles derived from the endogenous antioxidant and anti-inflammatory bile acid, bilirubin (BRNPs), in treating pulmonary fibrosis in a bleomycin-induced mouse model of the disease. Our results demonstrate that BRNPs can effectively reduce clinical signs in mice, as shown by histological, disease index evaluations, and detection of biomarkers. Our findings suggest that BRNPs, with their potent antioxidant and anti-inflammatory effects, long blood circulation half-life, and preferential accumulation at the inflamed site, are potentially a viable clinical option for preventing Covid-19 infection-associated pulmonary fibrosis. |*COVID-19[MESH] |*Pulmonary Fibrosis/drug therapy[MESH] |Animals[MESH] |Bilirubin[MESH] |Humans[MESH] |Mice[MESH] |Nanomedicine[MESH]A bilirubin-derived nanomedicine attenuates the pathological cascade o(epmc).pdf DeepDyve Pubget Overpricing